Hepatitis C virus: Here comes all-oral treatment

被引：22
作者：
O'Shea, Robert [1 ,2 ,3 ]
机构：
[1] Cleveland Clin, Inst Digest Dis, Dept Gastroenterol & Hepatol, Cleveland, OH 44195 USA
[2] Cleveland Clin, Inst Digest Dis, Transplantat Ctr, Cleveland, OH 44195 USA
[3] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2014年 / 81卷 / 03期
关键词：
TREATMENT-NAIVE PATIENTS; DIRECT-ACTING ANTIVIRALS; PHASE-2; TRIAL; UNITED-STATES; GENOTYPE; INFECTION; SOFOSBUVIR; THERAPY; RIBAVIRIN; HCV;
D O I：
10.3949/ccjm.81a.13155
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new direct-acting antivirals-sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)-opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.
引用
收藏
页码：159 / 172
页数：14
相关论文
共 39 条
[1]   The new paradigm of hepatitis C therapy: integration of oral therapies into best practices [J].
Afdhal, N. H. ;
Zeuzem, S. ;
Schooley, R. T. ;
Thomas, D. L. ;
Ward, J. W. ;
Litwin, A. H. ;
Razavi, H. ;
Castera, L. ;
Poynard, T. ;
Muir, A. ;
Mehta, S. H. ;
Dee, L. ;
Graham, C. ;
Church, D. R. ;
Talal, A. H. ;
Sulkowski, M. S. ;
Jacobson, I. M. .
JOURNAL OF VIRAL HEPATITIS, 2013, 20 (11) :745-760
[2]   New Horizons in Hepatitis C Antiviral Therapy With Direct-Acting Antivirals [J].
Aghemo, Alessio ;
De Francesco, Raffaele .
HEPATOLOGY, 2013, 58 (01) :428-438
[3]   Interferon free therapy with direct acting antivirals for HCV [J].
Asselah, Tarik ;
Marcellin, Patrick .
LIVER INTERNATIONAL, 2013, 33 :93-104
[4]   Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States [J].
Averhoff, Francisco M. ;
Glass, Nancy ;
Holtzman, Deborah .
CLINICAL INFECTIOUS DISEASES, 2012, 55 :S10-S15
[5]   Replication of hepatitis C virus [J].
Bartenschlager, R ;
Lohmann, V .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :1631-1648
[6]   Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C:: A meta-analysis of individual patient data [J].
Cammà, C ;
Di Bona, D ;
Schepis, F ;
Heathcote, EJ ;
Zeuzem, S ;
Pockros, PJ ;
Marcellin, P ;
Balart, L ;
Alberti, A ;
Craxì, A .
HEPATOLOGY, 2004, 39 (02) :333-342
[7]   Hepatitis C virus therapy update 2013 [J].
Casey, Lisa C. ;
Lee, William M. .
CURRENT OPINION IN GASTROENTEROLOGY, 2013, 29 (03) :243-249
[8]   HCV Treatment - No More Room for Interferonologists? [J].
Drenth, Joost P. H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20) :1931-1932
[9]   Emerging treatments for hepatitis C [J].
Flisiak, Robert ;
Jaroszewicz, Jerzy ;
Parfieniuk-Kowerda, Anna .
EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (04) :461-475
[10]   Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C [J].
Gane, Edward J. ;
Stedman, Catherine A. ;
Hyland, Robert H. ;
Ding, Xiao ;
Svarovskaia, Evguenia ;
Symonds, William T. ;
Hindes, Robert G. ;
Berrey, M. Michelle .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (01) :34-44
1234